EUVIMEDEUVIMED entdecken
Crossref

Glutathione Precursor Supplementation with Immunocal® for Inflammaging: An Open-Label Pilot Study Assessing suPAR Modulation in Middle-Aged Adults

María Soledad Andrés, Miguel Graber, Francisco Mera Cordero

Journal of Clinical Medical Research · 23.03.2026 · 7 (1) · 1-5

DOI: 10.46889/jcmr.2026.7113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medical Research, online erschienen am 23.03.2026. Verfasst von María Soledad Andrés und 2 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic low-grade systemic inflammation constitutes a central biological feature of aging and a key factor in the development of multiple chronic diseases [1,2]. The soluble urokinase Plasminogen Activator Receptor (suPAR) has emerged as a robust biomarker of chronic systemic inflammation and biological vulnerability [3-5]. Nutritional strategies aimed at modulating intracellular redox balance may influence upstream inflammatory pathways involved in the regulation of suPAR [6-9].

Objective

To explore whether supplementation with a cysteine-rich whey protein isolate, a glutathione precursor, is associated with changes in circulating suPAR concentrations and health-related quality of life in adults.

Methods

An exploratory, open-label, single-arm, longitudinal pre-post intervention proof-of-concept study. Twelve adult participants received oral supplementation with a cysteine-rich whey protein isolate (Immunocal®) for three months. Circulating suPAR concentrations and health-related quality of life, assessed using the SF-36 questionnaire, were measured at baseline and at the end of the intervention.

Results

After three months of supplementation, mean suPAR levels decreased from 3.19 to 1.87 ng/mL (mean Δ = 1.31; p < 0.0001). Mean total SF-36 scores increased from 71.77 to 87.39 (mean Δ = 15.61; p < 0.0001). The intervention was well tolerated and no serious adverse events were reported.

Conclusion

Supplementation with glutathione precursors using Immunocal® for a three-month period was associated with a significant reduction in circulating suPAR concentrations, a consolidated biomarker of chronic systemic inflammation and immune activation, as well as with concomitant improvements in health-related quality of life in adults.

Zitieren

APA

Andrés, M. S., Graber, M., & Cordero, F. M. (2026). Glutathione Precursor Supplementation with Immunocal® for Inflammaging: An Open-Label Pilot Study Assessing suPAR Modulation in Middle-Aged Adults. Journal of Clinical Medical Research, 7(1), 1-5. https://doi.org/10.46889/jcmr.2026.7113

Vancouver

Andrés MS, Graber M, Cordero FM. Glutathione Precursor Supplementation with Immunocal® for Inflammaging: An Open-Label Pilot Study Assessing suPAR Modulation in Middle-Aged Adults. Journal of Clinical Medical Research. 2026;7(1):1-5. doi:10.46889/jcmr.2026.7113

BibTeX
@article{Andrs2026,
  author = {Andrés, María Soledad and Graber, Miguel and Cordero, Francisco Mera},
  title = {Glutathione Precursor Supplementation with Immunocal® for Inflammaging: An Open-Label Pilot Study Assessing suPAR Modulation in Middle-Aged Adults},
  journal = {Journal of Clinical Medical Research},
  year = {2026},
  volume = {7},
  number = {1},
  pages = {1--5},
  doi = {10.46889/jcmr.2026.7113}
}
Kostenlos starten →